Sanofi Shares Outstanding 2010-2024 | SNY
Sanofi shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Sanofi shares outstanding for the quarter ending September 30, 2024 were 2.506B, a 0.02% decline year-over-year.
- Sanofi 2023 shares outstanding were 2.513B, a 0.04% decline from 2022.
- Sanofi 2022 shares outstanding were 2.514B, a 0.08% decline from 2021.
- Sanofi 2021 shares outstanding were 2.516B, a 0.17% decline from 2020.
Sanofi Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
2,513 |
| 2022 |
2,514 |
| 2021 |
2,516 |
| 2020 |
2,520 |
| 2019 |
2,514 |
| 2018 |
2,510 |
| 2017 |
2,534 |
| 2016 |
2,592 |
| 2015 |
2,641 |
| 2014 |
2,662 |
| 2013 |
2,675 |
| 2012 |
2,656 |
| 2011 |
2,643 |
| 2010 |
2,611 |
| 2009 |
2,612 |
Sanofi Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
2,506 |
| 2024-06-30 |
2,500 |
| 2024-03-31 |
2,498 |
| 2023-12-31 |
2,513 |
| 2023-09-30 |
2,506 |
| 2023-06-30 |
2,501 |
| 2023-03-31 |
2,499 |
| 2022-12-31 |
2,514 |
| 2022-09-30 |
2,507 |
| 2022-06-30 |
2,502 |
| 2022-03-31 |
2,498 |
| 2021-09-30 |
2,509 |
| 2021-06-30 |
|
| 2021-03-31 |
2,499 |
| 2020-09-30 |
2,511 |
| 2020-03-31 |
2,503 |
| 2019-09-30 |
2,504 |
| 2019-03-31 |
2,498 |
| 2018-03-31 |
2,496 |
| 2017-12-31 |
2,534 |
| 2017-09-30 |
2,509 |
| 2017-06-30 |
2,516 |
| 2017-03-31 |
2,525 |
| 2016-12-31 |
2,592 |
| 2016-09-30 |
2,577 |
| 2016-06-30 |
2,574 |
| 2016-03-31 |
2,577 |
| 2015-09-30 |
2,611 |
| 2015-06-30 |
2,612 |
| 2014-06-30 |
2,634 |
| 2013-06-30 |
2,691 |
| 2012-06-30 |
2,631 |
| 2012-03-31 |
2,642 |
| 2011-12-31 |
2,660 |
| 2011-09-30 |
2,678 |
| 2011-06-30 |
2,588 |
| 2011-03-31 |
2,614 |
| 2010-12-31 |
2,610 |
| 2010-09-30 |
2,610 |
| 2010-06-30 |
2,606 |
| 2010-03-31 |
2,609 |
| 2009-12-31 |
2,614 |
| 2009-09-30 |
2,611 |
| 2009-06-30 |
2,611 |
| 2009-03-31 |
2,609 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
